<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812160</url>
  </required_header>
  <id_info>
    <org_study_id>Spatz-160061</org_study_id>
    <nct_id>NCT02812160</nct_id>
  </id_info>
  <brief_title>Spatz Adjustable Balloon for Obesity (SABO)</brief_title>
  <acronym>SABO</acronym>
  <official_title>A Randomized, Controlled, Multicenter Study Comparing the Spatz3 Adjustable Balloon System Plus Diet and Exercise to Diet and Exercise Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spatz FGIA, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spatz FGIA, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Spatz3 Adjustable balloon, a&#xD;
      non-surgical device, is effective in the treatment of obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Device Name: Spatz3 Adjustable Balloon System® (Spatz3) Clinical Phase: Pivotal Trial Design:&#xD;
      Multicenter open-label randomized controlled trial Trial Participants: Adults, ages 22-65,&#xD;
      with a BMI ≥ 30 and &lt; 40 who have failed to achieve and maintain weight-loss with a weight&#xD;
      control program Control group: Supervised diet and exercise Planned sample size: 282 subjects&#xD;
      randomized 2:1 to device/control study treatment duration: 32 weeks Primary endpoint: Percent&#xD;
      change in total body weight (%TBL) at 32 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2016</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Total Body Weight (%TBL) .</measure>
    <time_frame>32 weeks</time_frame>
    <description>The mean %TBL in the Spatz3 group should exceed the %TBL control group by 4.5%.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Spatz3 Adjustable Balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spatz3 Adjustable Balloon with Dietary and exercise counselling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Dietary and Exercise counselling</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spatz3 Adjustable Balloon</intervention_name>
    <description>An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed</description>
    <arm_group_label>Spatz3 Adjustable Balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 22 - 65&#xD;
&#xD;
          2. BMI ≥ 30 and &lt;40&#xD;
&#xD;
          3. Willingness to comply with the substantial lifelong dietary restrictions required by&#xD;
             the procedure&#xD;
&#xD;
          4. History of obesity (BMI ≥ 30) for at least 2 years&#xD;
&#xD;
          5. History of failure with non-surgical weight loss methods&#xD;
&#xD;
          6. Willingness to follow protocol requirements, including signed informed consent,&#xD;
             routine follow-up schedule, completing laboratory tests, completing diet counseling&#xD;
&#xD;
          7. Residing within a reasonable distance from the investigator's office and able to&#xD;
             travel to the investigator to complete all routine follow- up visits&#xD;
&#xD;
          8. Ability to give informed consent&#xD;
&#xD;
          9. Women of childbearing potential (i.e., not post-menopausal or surgically sterilized)&#xD;
             must agree to use adequate birth control methods. Acceptable birth control methods are&#xD;
             limited to hormonal contraceptives (oral, flexible vaginal ring, skin patch,&#xD;
             injection), diaphragms, IUDs, condoms with or without spermicide, and voluntary&#xD;
             abstinence. The method of birth control must be documented and verified at follow-up.&#xD;
             Should a treatment arm subject become pregnant during the implantation period, the&#xD;
             balloon will be extracted during the second trimester - the timing of which will be&#xD;
             determined via consultation with the subject's obstetrician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior gastrointestinal surgery with sequelae, i.e. obstruction, and/or adhesive&#xD;
             peritonitis or known abdominal adhesions.&#xD;
&#xD;
          2. Prior open or laparoscopic bariatric surgery.&#xD;
&#xD;
          3. Prior surgery of any kind on the esophagus, stomach or any type of hiatal hernia&#xD;
             surgery.&#xD;
&#xD;
          4. Any inflammatory disease of the gastrointestinal tract including esophagitis,&#xD;
             Barrett's esophagus, gastric ulceration, duodenal ulceration, cancer or specific&#xD;
             inflammation such as Crohn's disease.&#xD;
&#xD;
          5. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric&#xD;
             varices, congenital or acquired intestinal telangiectasis, or other congenital&#xD;
             anomalies of the gastrointestinal tract such as atresias or stenoses.&#xD;
&#xD;
          6. A gastric mass.&#xD;
&#xD;
          7. A hiatal hernia &gt; 2cm or severe or intractable gastro-esophageal reflux symptoms.&#xD;
&#xD;
          8. Acid reflux symptoms to any degree that require more than one medication for symptom&#xD;
             control.&#xD;
&#xD;
          9. A structural abnormality in the esophagus or pharynx such as a stricture or&#xD;
             diverticulum that could impede passage of the balloon alongside the endoscope.&#xD;
&#xD;
         10. Achalasia or any other severe esophageal motility disorder that may pose a safety risk&#xD;
             during the removal of the device&#xD;
&#xD;
         11. Severe coagulopathy.&#xD;
&#xD;
         12. Insulin-dependent diabetes (either Type 1 or Type 2) or a significant likelihood of&#xD;
             requiring insulin treatment in the following 12 months.&#xD;
&#xD;
         13. Subjects with any serious health condition unrelated to their weight that would&#xD;
             increase the risk of endoscopy&#xD;
&#xD;
         14. Chronic abdominal pain&#xD;
&#xD;
         15. Motility disorders of the GI tract such as gross esophageal motility disorders,&#xD;
             gastroparesis or intractable constipation&#xD;
&#xD;
         16. Hepatic insufficiency or cirrhosis&#xD;
&#xD;
         17. Serious or uncontrolled psychiatric illness or disorder that could compromise patient&#xD;
             understanding of or compliance with follow up visits and removal of the device after 8&#xD;
             months.&#xD;
&#xD;
         18. Alcoholism or drug addiction.&#xD;
&#xD;
         19. Patients unwilling to participate in an established medically-supervised diet and&#xD;
             behavior modification program, with routine medical follow-up.&#xD;
&#xD;
         20. Patients receiving daily prescribed treatment with aspirin, anti-inflammatory agents,&#xD;
             anticoagulants or other gastric irritants.&#xD;
&#xD;
         21. Patients who are unable or unwilling to take prescribed proton pump inhibitor&#xD;
             medication for the duration of the device implant.&#xD;
&#xD;
         22. Patients who are known to have, or suspected to have, an allergic reaction to&#xD;
             materials contained in the system.&#xD;
&#xD;
         23. Patients who have ever developed a serotonin syndrome and are currently taking any&#xD;
             drug known to affect the levels of serotonin in the body [e.g., selective serotonin&#xD;
             reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs),&#xD;
             monoamine oxidase inhibitors (MAOIs)] should not undergo placement of the device.&#xD;
&#xD;
         24. Patients who are pregnant or breast-feeding.&#xD;
&#xD;
         25. Subjects with Severe cardiopulmonary disease or other serious organic disease which&#xD;
             might include known history of coronary artery disease, Myocardial infarction within&#xD;
             the past 6 months, poorly-controlled hypertension, required use of NSAIDs&#xD;
&#xD;
         26. Subjects who have tested positive for H. Pylori.&#xD;
&#xD;
         27. Subjects taking medications on specified hourly intervals that may be affected by&#xD;
             changes to gastric emptying, such as anti-seizure or anti-arrhythmic medications&#xD;
&#xD;
         28. Subjects who are taking corticosteroids, immunosuppressants, and narcotics&#xD;
&#xD;
         29. Subjects who are taking diet pills&#xD;
&#xD;
         30. Use of an intragastric device prior to this study due to the potential increase in&#xD;
             risk associated with implantation of a balloon in a previously instrumented and&#xD;
             possibly scarred stomach.&#xD;
&#xD;
         31. Participation in any clinical study which could affect weight loss within the past 6&#xD;
             months due to the potential to confound findings.&#xD;
&#xD;
         32. Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery&#xD;
             disease.&#xD;
&#xD;
         33. Pre-existing respiratory disease such as chronic obstructive pulmonary disease (COPD),&#xD;
             pneumonia or cancer.&#xD;
&#xD;
         34. Diagnosis of autoimmune connective tissue disorder (e.g. lupus, erythematous,&#xD;
             scleroderma) or immunocompromised.&#xD;
&#xD;
         35. Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical&#xD;
             condition, in the opinion of the investigator because of an increased risk profile.&#xD;
&#xD;
         36. Specific diagnosed genetic or hormonal cause for obesity such as hypothyroidism or&#xD;
             Prader Willi syndrome&#xD;
&#xD;
         37. Eating disorders including night eating syndrome (NES), bulimia, binge eating&#xD;
             disorder, or compulsive overeating&#xD;
&#xD;
         38. Known history of endocrine disorders affecting weight&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barham AbuDayyeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher C Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgical Specialists of Louisiana</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoscopic MicroSurgery Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Womans Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Manhattan VA Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <results_first_submitted>April 4, 2021</results_first_submitted>
  <results_first_submitted_qc>May 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <disposition_first_submitted>October 20, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>November 11, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 16, 2020</disposition_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02812160/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Spatz3 Adjustable Balloon</title>
          <description>Spatz3 Adjustable Balloon with Dietary and exercise counselling&#xD;
Spatz3 Adjustable Balloon: An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Dietary and Exercise counselling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The overall number of baseline participants does not differ from the number of participants</population>
      <group_list>
        <group group_id="B1">
          <title>Spatz3 Adjustable Balloon</title>
          <description>Spatz3 Adjustable Balloon with Dietary and exercise counselling&#xD;
Spatz3 Adjustable Balloon: An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Dietary and Exercise counselling</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="187"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="288"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="8.9"/>
                    <measurement group_id="B2" value="44.0" spread="8.9"/>
                    <measurement group_id="B3" value="44.3" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres</description>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="2.6"/>
                    <measurement group_id="B2" value="35.8" spread="2.7"/>
                    <measurement group_id="B3" value="35.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Total Body Weight (%TBL) .</title>
        <description>The mean %TBL in the Spatz3 group should exceed the %TBL control group by 4.5%.</description>
        <time_frame>32 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Spatz3 Adjustable Balloon</title>
            <description>Spatz3 Adjustable Balloon with Dietary and exercise counselling&#xD;
Spatz3 Adjustable Balloon: An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Dietary and Exercise counselling</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Body Weight (%TBL) .</title>
          <description>The mean %TBL in the Spatz3 group should exceed the %TBL control group by 4.5%.</description>
          <units>TBL%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="7.2"/>
                    <measurement group_id="O2" value="3.3" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>32 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Spatz3 Adjustable Balloon</title>
          <description>Spatz3 Adjustable Balloon with Dietary and exercise counselling&#xD;
Spatz3 Adjustable Balloon: An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Dietary and Exercise counselling</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Nausea, Vomiting, Abdominal pain, Diarrhoea, Abdominal discomfort, Gastrooesophageal reflux , disease, Abdominal pain upper, Colitis</description>
                <counts group_id="E1" events="24" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>Dehydration, Failure to thrive, Hypokalaemia</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="2522" subjects_affected="184" subjects_at_risk="187"/>
                <counts group_id="E2" events="84" subjects_affected="32" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There are no overall Limitations and Caveats</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey Brooks MD</name_or_title>
      <organization>Spatz FGIA Inc.</organization>
      <phone>1-516-303-0613</phone>
      <email>jeff@spatzmedical.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

